| Schedule of reconciliation of the company's net income (loss) |
The table below shows a reconciliation of the Company’s net loss, including the significant expense categories regularly provided to and reviewed by the CODM, as computed under GAAP, to the Company’s net loss in the consolidated statements of operations and comprehensive loss (in thousands): | | | | | | | | | For the Year Ended | | | December 31, | | | 2025 | | 2024 | Direct research and development expenses by program: | | | | | | | TTI-101: | | | | | | | HCC | | $ | 3,183 | | $ | 8,583 | IPF | | | 4,683 | | | 6,703 | mBC | | | (262) | | | 2,182 | Preclinical, CMC, and other (unallocated) (1) | | | 688 | | | 969 | TTI-109 | | | 5,371 | | | 1,193 | Unallocated research and development expense: | | | | | | | Personnel costs | | | 3,329 | | | 2,988 | Consultant fees and other costs (2) | | | 1,019 | | | 1,032 | General and administrative expense: | | | | | | | Personnel costs | | | 3,505 | | | 2,085 | Other general and administrative expenses (3) | | | 5,232 | | | 2,372 | Interest income | | | (1,375) | | | (747) | Other (income) expense, net | | | (7,159) | | | 2,037 | Net loss | | $ | (18,214) | | $ | (29,397) |
| (1) | Preclinical, chemistry, manufacturing and control (CMC), and other (unallocated) costs include preclinical testing, CMC, and other direct research and development expenses that are not allocated to a specific program. |
| (2) | Consultant fees and other costs includes expenses incurred for research and development consultants as well as payroll costs for employees within the research and development function. |
| (3) | Other general and administrative expenses include professional fees, accounting services, rent, and other overhead and administrative expenses. |
|